The EU Just Gave Monsanto an Early Christmas Present

It renewed approval for the ag giant’s controversial weedkiller, Roundup.

A tractor sprays a field with iherbicides. sauletas/iStock

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily.

Genetically modified seed and pesticide giant Monsanto has had tough row to hoe lately. The company’s long-proposed marriage with German chemical giant Bayer is undergoing withering scrutiny by regulators in Europe and Brazil, likely putting off its consummation for months. Here in its home country, two states have imposed new rules that could limit the market for Monsanto’s latest blockbuster product, soybeans engineered to resist a controversial herbicide called dicamba. 

But on Monday, Monsanto got good news from across the Atlantic, when the European Union ended a long stalemate and voted to maintain approval for glyphosate, the globe’s most-used herbicide, for another five years. Monsanto owned the original patent on the chemical (which has since expired), and the company maintains a 40 percent share of the global glyphosate market. The European market for glyphosate is worth an annual $1.18 billion, Reuters reports

The voting process was chaotic, The New York Times reports. Germany voted for approval, but only after overcoming a split within its government. France voted nay, and when the result came in, President Emmanuel Macron took to Twitter to vow to ban it in France within three years, spicing his statement with the Trump-trolling hashtag, “#MakeOurPlanetGreatAgain.”

The vote was caught up in the ongoing controversy about whether glyphosate causes cancer. The European Food Safety Agency and the US Environmental Protection Agency (pre-Trump) say, probably not; while the International Agency for Research on Cancer, which evaluates potential carcinogens for the World Health Organization, calls it “probably carcinogenic to humans.” Here’s my look from last year at the subtle difference between how the EFSA and EPA on one side, and the IARC on the other, assessed the herbicide.

Meanwhile, in June, Reuters found that the IARC had finalized its assessment even though the US scientist who led the agency panel on glyphosate, Aaron Blair was aware of then-unpublished data suggesting that glyphosate didn’t seem to cause cancer after all—a controversy Kiera Butler covered at the time. 

Earlier this month, that research was finally published: A large, long-term study of pesticide applicators in North Carolina and Iowa, which found “no association” between glyphosate exposure and most cancers, and “some evidence of increased risk” of acute myeloid leukemia “among the highest exposed group.” The authors added that the potential link requires more study. The IARC, for its part, is standing by its assessment. 

PLEASE—BEFORE YOU CLICK AWAY!

“Lying.” “Disgusting.” “Scum.” “Slime.” “Corrupt.” “Enemy of the people.” Donald Trump has always made clear what he thinks of journalists. And it’s plain now that his administration intends to do everything it can to stop journalists from reporting things it doesn’t like—which is most things that are true.

We’ll say it loud and clear: At Mother Jones, no one gets to tell us what to publish or not publish, because no one owns our fiercely independent newsroom. But that also means we need to directly raise the resources it takes to keep our journalism alive. There’s only one way for that to happen, and it’s readers like you stepping up. Please do your part and help us reach our $150,000 membership goal by May 31.

payment methods

PLEASE—BEFORE YOU CLICK AWAY!

“Lying.” “Disgusting.” “Scum.” “Slime.” “Corrupt.” “Enemy of the people.” Donald Trump has always made clear what he thinks of journalists. And it’s plain now that his administration intends to do everything it can to stop journalists from reporting things it doesn’t like—which is most things that are true.

We’ll say it loud and clear: At Mother Jones, no one gets to tell us what to publish or not publish, because no one owns our fiercely independent newsroom. But that also means we need to directly raise the resources it takes to keep our journalism alive. There’s only one way for that to happen, and it’s readers like you stepping up. Please do your part and help us reach our $150,000 membership goal by May 31.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate